Working… Menu

The Headache Inducing Effects of Cilostazol on Migraine Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01841827
Recruitment Status : Completed
First Posted : April 29, 2013
Last Update Posted : June 6, 2014
Information provided by (Responsible Party):
Song Guo, Danish Headache Center

Brief Summary:
We will use Cilostazol as a tool to investigate its headache inducing effects in migraine patients.

Condition or disease Intervention/treatment Phase
Migraine Drug: Cilostazol Drug: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Health Services Research
Official Title: The Headache Inducing Effects of Cilostazol on Migraine Patients
Study Start Date : April 2013
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache Migraine
Drug Information available for: Cilostazol

Arm Intervention/treatment
Active Comparator: Cilostazol
Capsule of Cilostazol 200 mg are taken orally on each study day
Drug: Cilostazol
Other Name: Pletal

Placebo Comparator: Placebo
A capsule of placebo containing starch are taken orally on each study day.
Drug: Placebo

Primary Outcome Measures :
  1. The incidens of headache or migraine after adminstration of Cilostazol in migraine patients compared to placebo. [ Time Frame: Outcome measure will be done within 3 month. Final data will be presented within 6 months ]
    Rectruitment of 14 patients will be done during April and May. Experiments will be carried out in May and June. Each experiment day takes 1½ hour. Data analysis will be done in June and July. Final data will be presented within 6 months.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with migraine without aura according to the IHS criteria from 2004.
  • Healthy besides migraine

Exclusion Criteria:

  • Tension-type headache more than 3 days per month
  • Other types of primary headaches
  • Pregnancy
  • History of vascular diseases or psychiatric diseases.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01841827

Layout table for location information
Danish Headache Center & Department of Neurology
Copenhagen, Glostrup, Denmark, 2600
Sponsors and Collaborators
Danish Headache Center

Layout table for additonal information
Responsible Party: Song Guo, MD, Danish Headache Center Identifier: NCT01841827     History of Changes
Other Study ID Numbers: H-2-2013-033
First Posted: April 29, 2013    Key Record Dates
Last Update Posted: June 6, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Vasodilator Agents
Neuroprotective Agents
Protective Agents
Phosphodiesterase 3 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors